Chevy Chase Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$182M Sell
407,615
-748
-0.2% -$349K 0.52% 27
2025
Q4
$185M Sell
408,363
-10,146
-2% -$4.37M 0.5% 27
2025
Q3
$164M Sell
418,509
-22,418
-5% -$9.37M 0.45% 31
2025
Q2
$196M Sell
440,927
-2,121
-0.5% -$977K 0.57% 26
2025
Q1
$215M Sell
443,048
-1,653
-0.4% -$770K 0.69% 21
2024
Q4
$179M Sell
444,701
-2,160
-0.5% -$1M 0.55% 26
2024
Q3
$208M Sell
446,861
-6,568
-1% -$3.16M 0.64% 23
2024
Q2
$213M Buy
453,429
+9,604
+2% +$4.17M 0.68% 21
2024
Q1
$186M Sell
443,825
-1,124
-0.3% -$475K 0.61% 29
2023
Q4
$181M Buy
444,949
+14,311
+3% +$5.29M 0.65% 26
2023
Q3
$150M Buy
430,638
+14,744
+4% +$5.16M 0.59% 30
2023
Q2
$146M Buy
415,894
+77,125
+23% +$26M 0.55% 33
2023
Q1
$107M Buy
338,769
+122,740
+57% +$36.8M 0.42% 52
2022
Q4
$62.4M Buy
216,029
+59,356
+38% +$18.1M 0.27% 96
2022
Q3
$45.4M Buy
156,673
+2,149
+1% +$618K 0.19% 114
2022
Q2
$43.5M Buy
154,524
+1,312
+0.9% +$351K 0.18% 126
2022
Q1
$40M Buy
153,212
+462
+0.3% +$110K 0.14% 148
2021
Q4
$33.5M Sell
152,750
-6,536
-4% -$1.27M 0.11% 174
2021
Q3
$28.9M Sell
159,286
-5,666
-3% -$1.11M 0.1% 186
2021
Q2
$33.3M Sell
164,952
-9,520
-5% -$1.99M 0.11% 173
2021
Q1
$37.5M Sell
174,472
-14,332
-8% -$3.15M 0.13% 157
2020
Q4
$44.6M Sell
188,804
-17,366
-8% -$3.98M 0.16% 147
2020
Q3
$56.1M Sell
206,170
-15,023
-7% -$4.14M 0.22% 101
2020
Q2
$64.2M Sell
221,193
-7,558
-3% -$2.05M 0.26% 87
2020
Q1
$54.4M Buy
228,751
+2,526
+1% +$579K 0.25% 92
2019
Q4
$49.5M Sell
226,225
-1,493
-0.7% -$302K 0.19% 125
2019
Q3
$38.6M Sell
227,718
-464
-0.2% -$82.1K 0.16% 147
2019
Q2
$41.8M Sell
228,182
-1,222
-0.5% -$214K 0.17% 132
2019
Q1
$39.1M Buy
229,404
+2,476
+1% +$457K 0.16% 139
2018
Q4
$37.6M Sell
226,928
-17,032
-7% -$2.95M 0.18% 126
2018
Q3
$47M Sell
243,960
-4,440
-2% -$791K 0.19% 122
2018
Q2
$42.2M Buy
248,400
+159
+0.1% +$24.6K 0.18% 129
2018
Q1
$40.5M Sell
248,241
-4,775
-2% -$780K 0.18% 135
2017
Q4
$37.9M Sell
253,016
-922
-0.4% -$137K 0.16% 146
2017
Q3
$38.6M Buy
253,938
+5,763
+2% +$867K 0.17% 138
2017
Q2
$32M Buy
248,175
+4,702
+2% +$566K 0.15% 160
2017
Q1
$26.6M Buy
243,473
+8,933
+4% +$786K 0.13% 184
2016
Q4
$17.3M Buy
234,540
+3
+0% +$244 0.09% 251
2016
Q3
$20.5M Sell
234,537
-4,450
-2% -$421K 0.11% 219
2016
Q2
$20.6M Buy
238,987
+3,634
+2% +$314K 0.11% 213
2016
Q1
$18.7M Buy
235,353
+32,721
+16% +$2.96M 0.11% 224
2015
Q4
$25.5M Buy
202,632
+2,238
+1% +$270K 0.15% 158
2015
Q3
$20.9M Buy
200,394
+7,682
+4% +$987K 0.13% 183
2015
Q2
$23.8M Buy
192,712
+3,845
+2% +$485K 0.14% 177
2015
Q1
$22.3M Buy
188,867
+7,734
+4% +$927K 0.13% 190
2014
Q4
$21.5M Buy
181,133
+156
+0.1% +$17.6K 0.13% 184
2014
Q3
$20.3M Buy
180,977
+12,420
+7% +$1.18M 0.13% 188
2014
Q2
$16M Sell
168,557
-3,346
-2% -$235K 0.11% 211
2014
Q1
$12.2M Buy
171,903
+1,557
+0.9% +$123K 0.09% 266
2013
Q4
$12.7M Buy
170,346
+2,824
+2% +$197K 0.09% 241
2013
Q3
$12.7M Buy
+167,522
New +$13.3M 0.1% 225

Other funds holding VRTX

Chevy Chase Trust's VRTX Position: Q1 2026 in Review

Chevy Chase Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 0.18% in Q1 2026, selling an estimated $349K and leaving 407,615 shares worth $182M. The position accounts for 0.52% of the portfolio, ranked #27.

Chevy Chase Trust first reported a position in VRTX in Q3 2013 and has held it in 51 quarters since. The position peaked at $215M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Chevy Chase Trust held 407,615 shares of Vertex Pharmaceuticals worth $182M as of Q1 2026.
  • Chevy Chase Trust sold 748 Vertex Pharmaceuticals shares in Q1 2026, an estimated $349K.
  • Vertex Pharmaceuticals made up 0.52% of Chevy Chase Trust's portfolio in Q1 2026, its #27 holding.
  • Chevy Chase Trust first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • Chevy Chase Trust's Vertex Pharmaceuticals position peaked at $215M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Chevy Chase Trust's 13F filing for Q1 2026, filed 15 May 2026.